DoW Rare Cancers Idea Development Award
Dept. of Defense — CDMRP · Other Federal · HT942526RCRPIDA
Source: Grants.gov · View original posting ↗
- AwardWhat a single award can be worth — the funder's published per-award amount or floor–ceiling range.
- $7.3M total
- DeadlineFinal application due date.
- Nov 18, 2026
- Letter of intentDue date for the letter of intent (a short pre-application some funders require or request before the full proposal).
- —
- MechanismNIH activity code — the grant type (R01 research project, R21 exploratory, K series career development, F series fellowship, …).
- —
- DurationMaximum project period for a single award.
- —
- Expected awardsHow many awards the funder anticipates making under this opportunity.
- 15
- Funding cycleHow often the program accepts applications (annual, multiple cycles per year, rolling, or one-time).
- Unknown
- Open dateWhen applications open (or opened).
- Jun 17, 2026
- Total fundingThe overall pool the funder expects to commit across ALL awards under this opportunity — not what one project receives.
- $7.3M total
- Clinical trialWhether proposed projects must, may, or must not include a clinical trial.
- Unspecified
Description
Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Idea Development Award (IDA) promotes ideas that are ready for further development and have the potential to yield high-impact findings and new avenues of investigation. Distinctive Features: The RCRP encourages applicants to include an exploratory aim or sub-aim to support any necessary discovery-driven research. Preliminary data with disease-specific rationale are required. However, these data do not necessarily need to originate from studies of the proposed rare cancer type(s)/subtype(s) under study. Research should have high potential impact on rare cancers and the patient community.